Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New stent system improves quality of life for oesophageal cancer patients

Cook : 29 May, 2008  (New Product)
Cook Medical has been granted 510(k) clearance from the US FDA for use of the Evolution Controlled Release Esophageal Stent System which was designed to improve the quality of life for patients with oesophageal cancer.
Evolution employs the first and only Stent delivery system that enables deployment and recapturability of the Stent with unprecedented precision. The ability to place the Stent precisely the first time may reduce the need for repeat procedures.

According to the American Cancer Institute, more than 16,000 new oesophageal cancer cases are presented every year in the US Risk factors for oesophageal cancer include alcohol consumption, lye indigestion, tobacco, GERD (gastroesophageal reflux disease) and obesity. Typically, an oesophageal Stent is used in the treatment of oesophageal cancer patients whose condition has advanced beyond surgical treatment options. The market for gastrointestinal stenting currently totals $200 million globally, more than fifty percent of which is in the USA.

“Evolution, including the Stent and delivery system, is a major step forward in oesophageal stenting, offering a new, improved alternative to the traditional push-pull deployment system,” said Dr Todd Baron, of Rochester, Minnesota, USA. “By enabling accurate placement of the Stent the first time with its unique delivery system, Evolution may reduce the need for repeat procedures”.

The Evolution stent's retractable delivery system facilitates direct monitoring of the placement progress throughout the procedure with it's ‘point-of-no-return’ indicator, allowing physicians more controlled placement of the stent. With each squeeze of the stent's trigger-based introducer, a proportional length of the Stent is deployed or recaptured. The directional button enables seamless switching from deployment to recapture mode and the ‘point-of-no-return’ mark alerts the physician when recapture is no longer available. However, even after this point repositioning is still an option.

The Evolution Stent is designed with dual flanges that secure the stent, potentially reducing the risk of migration or Stent movement after placement, thus eliminating the need for repeat procedures. The device is also the only oesophageal Stent with an internal and external silicone coating, designed to resist tumour ingrowth into the Stent and enhances the patients' ability to swallow food normally instead of eating through a tube.

“We are thrilled to introduce Evolution to the market as the first and only recapturable Stent deployment system,” said Barry Slowey, vice president of global sales and marketing for Cook Medical's Endoscopy division. “Since launching the first esophageal Stent more than 20 years ago, Cook has continued to pioneer new innovations in this market with the goal of improving patient care. With a unique set of features, like the ability to recapture, reposition and control the deployment of the stent, Evolution leapfrogs any other esophageal Stent system on the market today.”

The Evolution Stent is also cleared for use in Europe. Since its limited launch on February 18, 2008 in select centres, the Stent has been utilised in more than forty cases in seven different European countries.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo